TLDR
- AIFF expands 20x with 99 commercial users in 2025
- EEG scan volumes jump 33-fold year over year
- Evoke deal boosts clinical and data scale
- NVIDIA L40S GPUs power biomarker discovery push
- Database tops 191,000 standardized brain scans
Firefly (AIFF) stock traded at $1.80 an increase of 164% on March 4, 2026. The company reported a 20-fold expansion in its commercial footprint during 2025. It also recorded a 33-fold increase in EEG and ERP scan volumes.
Firefly Neuroscience, Inc., AIFF
The neuroscience technology company ended 2025 with 99 commercial users. These partners completed more than 10,800 EEG and ERP brain scans. The growth reflects sharp increases since the end of 2023.
Firefly attributed the expansion to internal initiatives and its acquisition strategy. It completed the acquisition of Evoke Neuroscience to strengthen its clinical base. As a result, the company accelerated both data generation and commercial adoption.
Commercial Network Scales Rapidly
Firefly increased partner sites by 1,880 percent year over year. At the same time, EEG and ERP clinical assessments rose 3,227 percent. These gains highlight strong uptake of its brain analytics platform.
The company focused on expanding access to its standardized EEG tools. It targeted clinics, research centers, and specialized neurological practices. The commercial network widened across multiple healthcare segments.
Firefly integrates EEG and ERP analytics into routine clinical workflows. Providers use the system to support diagnosis and treatment monitoring. The platform generates recurring scan volumes and data accumulation.
The Evoke Neuroscience acquisition played a central role in scaling operations. The transaction added established clinical relationships and infrastructure. It also enhanced distribution and operational capacity.
Firefly aligned Evoke’s capabilities with its proprietary analytics systems. This integration strengthened customer onboarding and service delivery. As a result, the company improved efficiency and expanded output.
The company now operates one of the largest standardized EEG repositories globally. Its database includes more than 191,000 brain scans. This foundation supports large-scale analytics and model development.
Data Growth Supports Biomarker Development
Firefly leverages its expanding dataset to advance biomarker discovery. It applies advanced computing to identify patterns linked to neurological and mental disorders. These efforts support research in depression, dementia, anxiety, concussions, and ADHD.
The company deploys NVIDIA L40S GPU acceleration to process EEG data faster. This hardware upgrade improves signal processing and model training speeds. Firefly enhances analytical precision and scalability.
Management stated that the platform builds a clean and standardized dataset. It emphasized the importance of structured data for clinical development. The company prioritizes data integrity and consistency.
The growing volume of EEG and ERP scans strengthens model training capacity. Each scan contributes additional signal diversity and diagnostic insight. This cumulative effect increases algorithm robustness.
Firefly continues to refine its AI-driven brain analytics tools. Its technology holds FDA 510(k) clearance for specific clinical applications. That regulatory clearance supports broader clinical adoption.
The company aims to transform neuroscience research through scalable analytics. It positions its dataset as a competitive advantage in cognitive biomarker development. It integrates hardware acceleration with data growth strategies.
Foundation Model Ambition Gains Momentum
Firefly advances plans to build an EEG and ERP-based foundation model of the human brain. The company believes its expanding dataset enables this objective. It combines large-scale data with accelerated computing infrastructure.
The foundation model initiative seeks to map cognitive and neurological patterns. It intends to support earlier detection and improved monitoring of disorders. The company aligns commercial growth with long-term research goals.
Firefly connects clinical scan expansion to model training pipelines. Each commercial deployment adds new standardized data points. This process creates a feedback loop between revenue and research.
The company maintains a focused strategy on brain health analytics. It concentrates on scalable tools for clinicians and researchers. As a result, Firefly aligns commercial objectives with scientific advancement.
Its AI-driven EEG platform differentiates it within digital health markets. The database scale supports comparative analytics across populations. This capability strengthens both research and clinical applications.
Firefly closed 2025 with measurable operational expansion and higher data throughput. The 20-fold commercial growth and 33-fold scan increase mark a pivotal year. The company now moves forward with enhanced computing power and expanding clinical reach.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
